Ownership and insider activity for Apimeds Pharmaceuticals US, Inc (APUS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
Price
| Price | $1.60 |
| Market Cap | $2M |
| Exchange | AMEX |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2024-05-12 | Inscobee Inc. | |||
| 2025-11-11 | Weintraub Bennett | A-Award | 10,000 | $27K |
| 2025-11-11 | Yoon Hankil | A-Award | 10,000 | $27K |
| 2025-11-11 | Koo Jakap | A-Award | 10,000 | $27K |
| 2025-11-11 | O'DONNELL CAROL A | A-Award | 10,000 | $27K |
| 2025-11-11 | Kogan Elona | A-Award | 10,000 | $27K |
| 2025-10-15 | Kogan Elona | A-Award | 3,000 | $6K |
| 2025-10-15 | O'DONNELL CAROL A | A-Award | 3,000 | $6K |
| 2025-10-15 | Koo Jakap | A-Award | 3,000 | $6K |
| 2025-10-15 | Weintraub Bennett | A-Award | 3,000 | $6K |
Balance Sheet (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $171438 | $6171 | $410481 | $3455 | $1.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | $2.0M |
| Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $172169 | $6171 | $422076 | $13057 | $14.0M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | $239021 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $172169 | $6171 | $422076 | $13057 | $164.2M |
| Accounts Payable | $10652 | $36877 | 0 | 0 | $918649 |
| Short-term Debt | 0 | $260000 | 0 | $250000 | $7.6M |
| Total Current Liabilities | $10652 | $319777 | $123314 | $1.0M | $10.7M |
| Long-term Debt | $400000 | $400000 | $266891 | $346844 | 0 |
| Total Liabilities | $410652 | $719777 | $390205 | $1.4M | $10.8M |
| Retained Earnings | -$1.6M | -$2.2M | -$3.0M | -$4.4M | -$10.4M |
| Total Equity | -$238483 | -$713606 | $31871 | -$1.4M | $153.3M |
| Total Debt | $400000 | $660000 | $266891 | $596844 | $7.8M |
| Net Debt | $228562 | $653829 | -$143590 | $593389 | $4.1M |
| Working Capital | $161517 | -$313606 | $298762 | -$1.0M | $3.3M |
Financial Health
| Debt / Equity | 0.14 |
| Current Ratio | 0.51 |
Profitability
| Return on Equity | -58.98% |
| Return on Invested Capital | -15.89% |
| Return on Assets | -45.58% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANTX · IGC · MIRA · MLSS · MYO · NXTC · POCI
Explore sector: Healthcare · Biotechnology
More sections of APUS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks